Global portfolio Viatris operates a dynamic portfolio spanning generics, established brands, and innovative medicines, indicating multiple cross-sell opportunities across diverse therapeutic areas and lifecycle management for healthcare systems worldwide.

Cash generation Strong reported cash flow and deleveraging progress suggest capacity for increased commercial investments, partnerships, and potential co-development or licensing deals to accelerate growth and expand the pipeline.

Scale coverage A multinational footprint with centers in the US, China, and India enables regional market access strategies, supply-chain collaborations, and favorable pricing negotiations across high-volume markets.

Pipeline momentum Recent pipeline progress and upcoming Phase 3 milestones offer opportunities for strategic alliances, regional rights, or milestone-based partnerships to monetize near-term assets.

Sustainability alignment Viatris sustainability and corporate responsibility initiatives can be leveraged to position co-development or supply agreements with health systems prioritizing ESG-aligned suppliers.